Telltale signs of progress in the management of thrombotic thrombocytopenic purpura

Transfusion. 2012 Dec;52(12):2498-501. doi: 10.1111/j.1537-2995.2012.03946.x.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Female
  • Hemolytic-Uremic Syndrome / mortality*
  • Hemolytic-Uremic Syndrome / therapy*
  • Humans
  • Male
  • Plasma Exchange / adverse effects*
  • Plasma Exchange / mortality*
  • Purpura, Thrombotic Thrombocytopenic / drug therapy*
  • Purpura, Thrombotic Thrombocytopenic / mortality*
  • Purpura, Thrombotic Thrombocytopenic / therapy*
  • Rituximab

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab